Real-World Safety of JAK Inhibitors in Skin Immune-Mediated Inflammatory Diseases: Boxed Warning Outcomes from a Multinational Cohort Study - PubMed
3 hours ago
- #safety study
- #JAK inhibitors
- #skin diseases
- JAK inhibitors (JAKis) are effective for skin immune-mediated inflammatory diseases (IMIDs) but have safety concerns due to boxed warnings from rheumatoid arthritis trials.
- A multinational retrospective cohort study compared JAKis with conventional immunomodulators (cIMs) in patients with skin IMIDs (psoriatic disease, atopic dermatitis, or alopecia areata).
- The study included 17,068 propensity score-matched patients and found JAKis had lower incidences of all-cause mortality (0.28% vs. 0.62%) and major adverse cardiovascular events (MACE; 1.15% vs. 1.95%) over 2 years compared to cIMs.
- Risks of venous thromboembolism and malignancy were not increased with JAKis.
- Subgroup analyses, including older adults and those with cardiometabolic risk factors, showed no increased risk, consistent across agent-level and sensitivity analyses.
- The results suggest JAKis are not associated with increased risks of mortality, MACE, venous thromboembolism, or malignancy compared to conventional systemic agents in skin IMIDs over 2 years.